4D Molecular Ownership
| FDMT Stock | USD 3.93 0.01 0.26% |
Shares in Circulation | First Issued 2019-09-30 | Previous Quarter 55.6 M | Current Value 53.9 M | Avarage Shares Outstanding 32.3 M | Quarterly Volatility 12.9 M |
FDMT |
FDMT Stock Ownership Analysis
About 96.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.36. Some equities with similar Price to Book (P/B) outperform the market in the long run. 4D Molecular Therapeutics recorded a loss per share of 2.98. The entity had not issued any dividends in recent years. 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. The company was founded in 2013 and is headquartered in Emeryville, California. 4D Molecular operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 138 people. To learn more about 4D Molecular Therapeutics call David MD at 510 505 2680 or check out https://www.4dmoleculartherapeutics.com.FDMT Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as 4D Molecular is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading 4D Molecular Therapeutics backward and forwards among themselves. 4D Molecular's institutional investor refers to the entity that pools money to purchase 4D Molecular's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Redmile Group, Llc | 2024-12-31 | 1.2 M | Casdin Capital, Llc | 2024-12-31 | 1.1 M | State Street Corp | 2024-12-31 | 1.1 M | Geode Capital Management, Llc | 2024-12-31 | 1 M | Jpmorgan Chase & Co | 2024-12-31 | 820.1 K | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-12-31 | 794.6 K | Assenagon Asset Management Sa | 2024-12-31 | 653.5 K | Deep Track Capital, Lp | 2024-12-31 | 609.9 K | Citadel Advisors Llc | 2024-12-31 | 605.1 K | Blackrock Inc | 2024-12-31 | 4.9 M | Ra Capital Management, Llc | 2024-12-31 | 4.6 M |
4D Molecular Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific 4D Molecular insiders, such as employees or executives, is commonly permitted as long as it does not rely on 4D Molecular's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases 4D Molecular insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
4D Molecular Outstanding Bonds
4D Molecular issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. 4D Molecular Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most FDMT bonds can be classified according to their maturity, which is the date when 4D Molecular Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
4D Molecular Corporate Filings
F4 | 10th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 28th of February 2025 Other Reports | ViewVerify | |
| 14th of February 2025 Other Reports | ViewVerify | |
8K | 10th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for FDMT Stock Analysis
When running 4D Molecular's price analysis, check to measure 4D Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4D Molecular is operating at the current time. Most of 4D Molecular's value examination focuses on studying past and present price action to predict the probability of 4D Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4D Molecular's price. Additionally, you may evaluate how the addition of 4D Molecular to your portfolios can decrease your overall portfolio volatility.